
Italfarmaco and JCR Pharmaceuticals Sign Exclusive License Deal for Hunter Syndrome Therapy
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. announced an exclusive…














